Cloud-Clone pitches PCNA antibody as a multi-platform research tool

Cloud-Clone is highlighting a validated PCNA monoclonal antibody for research in DNA repair, cell proliferation and cancer. The company says the reagent works across Western blot, tissue staining and immunofluorescence, with potential use in translational oncology and liquid biopsy studies.

Why it matters: - PCNA is a core protein tied to DNA replication, DNA repair and cell-cycle progression. - The protein is widely used as a marker of cell proliferation and is relevant to cancer, pathology and autoimmune research. - A validated antibody can improve consistency across experiments that depend on detecting PCNA in different sample types.

What happened: - Cloud-Clone is promoting its PCNA monoclonal antibody, CAA591Hu22 / MAB231Hu22, as a multi-application reagent for basic biology and translational research. - The antibody has been validated for Western blot, IHC-P and immunofluorescence. - The product is positioned for researchers studying DNA metabolism, cancer prognosis and liquid biopsy.

The details: - In Western blot testing at 1 μg/mL, the antibody detected specific bands at about 36 kDa in tissue lysates from seven species, including rat lung, porcine kidney, canine lung, bovine testis, goat lung and equine liver. - The cross-species results are presented as evidence of antibody specificity and the evolutionary conservation of PCNA. - In IHC-P, rat-testis sections stained with 30 μg/mL primary antibody showed brown nuclear signals in spermatogonia along the basement membrane of seminiferous tubules. - The PBS negative control showed negligible background. - In immunofluorescence, human MCF-7 breast-cancer cells stained with 20 μg/mL primary antibody and 0.75 μg/mL FITC-labelled secondary antibody showed granular nuclear PCNA signals with low background. - The company says optimized matched secondary-antibody products, including HRP- or FITC-labelled reagents such as SAA544Mu19, are available to support reproducible results. - The company directs researchers to its website for validation datasets, product specifications and matching-reagent options. More information is available on Cloud-Clone's website. - The company also lists social media and contact channels, including LinkedIn, Instagram, TikTok, another LinkedIn profile, another Instagram profile, another TikTok profile and X.

Between the lines: - The pitch goes beyond a standard reagent launch and frames PCNA as a pan-cancer biomarker, a therapeutic target and an autoimmune research target. - That broader framing is designed to connect a single antibody product to multiple research workflows, from mechanistic cell biology to clinical biomarker work. - The release cites published studies suggesting PCNA can appear in exosomes and peripheral circulation, which could support non-invasive screening approaches. - The release also points to one published study reporting 94.4% detection specificity, but does not identify the study in the body text. - The therapeutic angle is reinforced by references to PCNA-targeting small molecules such as AOH1996 showing anti-tumor effects in vitro and in vivo.

What's next: - Cloud-Clone is encouraging global researchers to use the antibody for DNA-damage repair studies, tumor-diagnostic work and translational oncology. - The company says full validation data and matched reagents are available through its website. - Further adoption will likely depend on how well the antibody performs across additional sample types, platforms and research settings.

The bottom line: - Cloud-Clone is packaging PCNA as more than a textbook replication protein, and the antibody as a versatile tool for work spanning cell biology, oncology and autoimmune disease.